Pharvaris (PHVS) Current Leases (2021 - 2026)
Pharvaris' (PHVS) quarterly Current Leases came in at $241537.7 in Q1 2026, up 18.0% YoY from $204695.7 in Q1 2025, and up 3.64% on a QoQ basis from $233056.6 in Q4 2025.
Analysis
Pharvaris (PHVS) Current Leases (2021 - 2026) Analysis & Trends
Pharvaris (PHVS) has 6 years of Current Leases data on file, last reported at $241537.7 in Q1 2026.
- Quarterly Current Leases rose 18.0% year-over-year to $241537.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $241537.7 (up 18.0% YoY) and the FY2025 annual result came in at $226202.9, down 6.04% from the prior year.
- Current Leases rose to $241537.7 in Q1 2026, from $233056.6 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $248405.4 in Q2 2023 to a low of $104057.5 in Q2 2024.
- A 5-year average of $179872.2 and a median of $191198.4 in 2022 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2023 — Current Leases surged 114.24% — and 2024, when it sank 58.11%.
- Tracing PHVS's Current Leases over 5 years: stood at $191198.4 in 2022, then grew by 9.93% to $210175.2 in 2023, then advanced by 13.09% to $237684.5 in 2024, then decreased by 1.95% to $233056.6 in 2025, then increased by 3.64% to $241537.7 in 2026.
- The last three Current Leases figures came in at $241537.7 (Q1 2026), $233056.6 (Q4 2025), and $160881.9 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Pharvaris | 2.10 Bn | 1.73 Bn | 85,072.10 | 223.63 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 223.63 Bn |
| Mar 31, 2026 | 241.54 Bn |
| Dec 31, 2025 | 233.06 Bn |
| Sep 30, 2025 | 160,881.85 |
| Jun 30, 2025 | 182,861.30 |
| Mar 31, 2025 | 204,695.66 |
| Dec 31, 2024 | 237.68 Bn |
| Sep 30, 2024 | 109,205.85 |
| Jun 30, 2024 | 104,057.49 |
| Mar 31, 2024 | 130,864.22 |
| Dec 31, 2023 | 210.18 Bn |
| Sep 30, 2023 | -212,646.35 |
| Jun 30, 2023 | 248.41 Bn |
| Mar 31, 2023 | -244,850.74 |
| Dec 31, 2022 | 191.20 Bn |
| Sep 30, 2022 | 113,216.10 |
| Jun 30, 2022 | 118,200.00 |
| Mar 31, 2022 | 114,289.89 |
| Dec 31, 2021 | 113.75 Bn |
| Sep 30, 2021 | -121,323.90 |